All news

Perrigo guides all-in adjusted EPS to $2.25-$2.45 as infant formula moves to discontinued operations

Seeking Alpha · · AI-summarised by FinFlash

Perrigo expects 2026 all-in adjusted EPS of $2.25-$2.45 after shifting its infant formula business into discontinued operations, Seeking Alpha reports from the earnings call. The consumer health group's third-quarter all-in adjusted EPS fell 25% to $0.60, ahead of estimates, on revenue of $989 million from continuing operations. Shares were listed up 0.83%. The reclassification reflects the planned divestiture of the formula unit, which changes the base investors use to measure the company.

So What?

Exiting infant formula narrows Perrigo to over-the-counter health, and the new guidance base complicates comparisons. Watch sale terms and how proceeds are used.

Read original source

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.